Cart
sales@molnova.com
Bcl-xL antagonist 2
CAS No. 1235032-75-3
Bcl-xL antagonist 2( —— )
Catalog No. M28193 CAS No. 1235032-75-3
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 335 | Get Quote |
|
| 10MG | 500 | Get Quote |
|
| 25MG | 806 | Get Quote |
|
| 50MG | 1098 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 500MG | 2961 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBcl-xL antagonist 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionBcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
-
DescriptionBcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.(In Vivo):Bcl-xL antagonist 2 (1 mg/kg;i.v.) exhibits good PK profile with CL, Vss, t1/2 and F of 0.47 mL/min/kg, 0.16L/kg, 6.0 h and 16% in rats.
-
In Vitro——
-
In VivoAssessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1235032-75-3
-
Formula Weight436.51
-
Molecular FormulaC21H16N4O3S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (143.18 mM)
-
SMILESO=C(O)C=1N=C(SC1)N2CC=3C(=CC=CC3CC2)C(=O)NC4=NC=5C=CC=CC5S4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7.
molnova catalog
related products
-
BTSA1
BTSA1 is a BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.
-
Disarib
Disarib is a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.
-
Desmorpholinyl Navit...
Desmorpholinyl Navitoclax-NH-Me is a Bcl-xL inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 .
